Localized scleroderma secondary to mixed connective tissue disease during abatacept therapy

A 47‐year‐old woman with mixed connective tissue disease was treated with abatacept. After 2 months, a 3‐cm depression with atrophied surface was observed on her back, which had histopathological consistent with the symptoms of localized scleroderma. Although some cases of paradoxical reaction or cutaneous adverse event have been reported from abatacept, no localized scleroderma has been reported, suggesting this to be a unique case

Brentuximab vedotin treatment for mycosis fungoides with CD30+ large‐cell transformation in the early stage

In this paper, we bring hope to patients with mycosis fungoides (MF) with CD30+ large‐cell transformation (LCT), which is often a histological marker of poor prognosis and is associated with a mean 5‐year survival of <20%. Although skin biopsy is a painful procedure, it is the only test for early diagnosis of LCT. Stage IIB has a significantly worse 5‐year survival rate compared with stage IB/IIA, which often plagues clinicians regarding appropriate treatment selection. In this case, the discovery of LCT by skin biopsy prompted treatment with BV. Thus, proactive rebiopsy is important so that CD30+ LCT is not overlooked in the early stage of MF

Hydroxyzine‐induced fixed drug eruption and cross‐reaction with oxatomide

There are a few reports in the literature implicating them in causing fixed drug eruption, the piperazine derivatives. In this case, although eszopiclone for insomnia medicinehas a piperazine ring, no eruption appeared so far. Oxatomide and hydroxyzine not only shared a piperazine ring but also shared two benzene rings via a methine group (=CH–). It was suspected that this shared structural group became an antigenic determinant and resulted in cross‐reactivity. Such a unique case has not been reported before